-- Summary
‘Vulvovaginal Candidiasis - Pipeline Review, H2 2016’, provides an overview of the Vulvovaginal Candidiasis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/685903-vulvovaginal-candidiasis-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
- The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685903-vulvovaginal-candidiasis-pipeline-review-h2-2016
Key points in table of content
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vulvovaginal Candidiasis Overview 7
Therapeutics Development 8
Pipeline Products for Vulvovaginal Candidiasis - Overview 8
Vulvovaginal Candidiasis - Therapeutics under Development by Companies 9
Vulvovaginal Candidiasis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Vulvovaginal Candidiasis - Products under Development by Companies 13
Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 14
Cidara Therapeutics, Inc. 14
Grupo Ferrer Internacional, S.A. 15
NovaDigm Therapeutics, Inc. 16
Scynexis, Inc. 17
TGV-Laboratories 18
Viamet Pharmaceuticals, Inc. 19
Vulvovaginal Candidiasis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(clotrimazole + diclofenac sodium) - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
arasertaconazole - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CD-101 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
MH-010 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Myc-102 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
NDV-3 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
NDV-3A - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SCY-078 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
TOL-463 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
VT-1161 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Vulvovaginal Candidiasis - Dormant Projects 48
Vulvovaginal Candidiasis - Discontinued Products 49
Vulvovaginal Candidiasis - Product Development Milestones 50
Featured News & Press Releases 50
Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685903
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Release ID: 139751
Google
RSS